Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$1.95 -5.8%	$1.68	$1.43 ▼ $4.69	$195.80M	1.57	152,968 shs	134,136 shs
CTMX CytomX Therapeutics	$2.75 -8.0%	$1.56	$0.40 ▼ $3.10	$221.71M	2.11	2.15 million shs	1.97 million shs
MNPR Monopar Therapeutics	$33.52 -0.9%	$37.17	$1.72 ▼ $54.30	$204.98M	0.99	358,397 shs	41,799 shs
TYME Tyme Technologies	$0.31	$0.30	$0.22 ▼ $1.14	$53.51M	0.93	1.01 million shs	2.68 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	-5.80%	-4.41%	+27.45%	-14.85%	-57.97%
CTMX CytomX Therapeutics	-8.03%	+4.17%	+15.55%	+323.34%	+84.56%
MNPR Monopar Therapeutics	-0.89%	-9.67%	-9.67%	+12.67%	+649.13%
TYME Tyme Technologies	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.9793 of 5 stars	3.5	3.0	0.0	0.0	3.3	0.8	1.3
CTMX CytomX Therapeutics	4.2761 of 5 stars	3.5	1.0	0.0	4.7	2.6	2.5	1.3
MNPR Monopar Therapeutics	2.8568 of 5 stars	3.4	5.0	0.0	0.0	2.0	2.5	0.0
TYME Tyme Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	515.38% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	93.94% Upside
MNPR Monopar Therapeutics	2.75	Moderate Buy	$55.33	65.08% Upside
TYME Tyme Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TYME, CTMX, MNPR, and ACIU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/1/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
4/3/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/2/2025	MNPR Monopar Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/1/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/19/2025	MNPR Monopar Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$76.00
3/14/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$28.30M	6.92	N/A	N/A	$2.12 per share	0.92
CTMX CytomX Therapeutics	$147.56M	1.50	N/A	N/A	($0.71) per share	-3.87
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$1.88 per share	N/A
TYME Tyme Technologies	N/A	N/A	N/A	N/A	$0.47 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$60.41M	-$0.58	N/A	N/A	N/A	N/A	-28.26%	-18.98%	8/5/2025 (Estimated)
CTMX CytomX Therapeutics	-$570K	$0.48	16.18	N/A	N/A	10.96%	-41.47%	8.11%	8/6/2025 (Estimated)
MNPR Monopar Therapeutics	-$8.40M	-$3.48	N/A	N/A	N/A	N/A	-107.21%	-87.57%	8/8/2025 (Estimated)
TYME Tyme Technologies	-$23.63M	-$0.14	N/A	∞	N/A	N/A	-28.30%	-26.21%	N/A

Latest TYME, CTMX, MNPR, and ACIU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
4/30/2025	Q1 2025	ACIU AC Immune	-$0.22	-$0.21	+$0.01	-$0.21	$1.99 million	$1.12 million
3/31/2025	Q4 2024	MNPR Monopar Therapeutics	-$0.36	-$2.23	-$1.87	-$2.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
TYME Tyme Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.86	1.86
CTMX CytomX Therapeutics	N/A	1.04	1.04
MNPR Monopar Therapeutics	N/A	5.41	5.41
TYME Tyme Technologies	N/A	14.06	14.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
CTMX CytomX Therapeutics	67.77%
MNPR Monopar Therapeutics	1.83%
TYME Tyme Technologies	16.69%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
CTMX CytomX Therapeutics	6.60%
MNPR Monopar Therapeutics	20.50%
TYME Tyme Technologies	16.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	94.39 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	3.97 million	Not Optionable
TYME Tyme Technologies	17	172.21 million	143.10 million	Optionable

TYME, CTMX, MNPR, and ACIU Headlines

Recent News About These Companies

Tyme caps off a tough year for African startups with a unicorn crown

January 12, 2025 | independent.co.ug

How Nubank’s Investment in Tyme Helps African Startups

January 8, 2025 | fintechmagazine.com

Nubank leads Tyme Group’s $250m Series D – valuing Tyme at $1.5bn

January 3, 2025 | intelligentcio.com

Tyme é avaliado em US$ 1,5 bi com apoio do Nubank, na África

December 18, 2024 | bloomberg.com

Brazil’s Nubank invests $150 million in Tyme Group to expand digital banking offerings

December 18, 2024 | msn.com

Brazilian bank Nubank makes a big R2.7bn investment in fintech Tyme Group

December 18, 2024 | msn.com

South African Tyme Group Becomes Africa’s Latest Unicorn After $250M Series D Funding

December 18, 2024 | msn.com

TymeBank parent valued at $1.5-billion in latest fundraise

December 17, 2024 | techcentral.co.za

Brazilian fintech giant invests in SA-born Tyme Group

December 17, 2024 | itnewsafrica.com

Multi-billion funding bolsters Tyme Group valuation

December 17, 2024 | itweb.co.za

Billionaire Patrice Motsepe’s Tyme worth $1.5 billion becomes Africa’s 9th unicorn

December 17, 2024 | nairametrics.com

Tyme, Owners Of TymeBank And GoTyme, Raises R4.5 Billion In Funding Led By NYSE-Listed Brazilian FinTech Nubank

December 17, 2024 | techfinancials.co.za

Brazilian fintech Nubank’s $150mn investment to give South Africa’s Tyme unicorn status

December 17, 2024 | ft.com

African digital bank Tyme raises $250M round led by Nubank at $1.5B valuation

December 17, 2024 | msn.com

Digital bank Tyme gains unicorn status with $250m Series D raise

December 17, 2024 | finance.yahoo.com

Nubank Announces Investment in Tyme Group, a Digital Bank With Operations in South Africa and the Philippines

December 16, 2024 | businesswire.com

Best Restaurants in Leominster, Massachusetts

November 10, 2024 | thetechedvocate.org

Best Restaurants in Quincy, Illinois

November 10, 2024 | thetechedvocate.org

Best Restaurants in Peoria, Illinois

November 9, 2024 | thetechedvocate.org

Eden Green herb program named on TIME’s Best Inventions of 2024 list

November 6, 2024 | producegrower.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYME, CTMX, MNPR, and ACIU Company Descriptions

AC Immune NASDAQ:ACIU

$1.95 -0.12 (-5.80%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.97 +0.02 (+1.03%)

As of 06/13/2025 07:50 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

CytomX Therapeutics NASDAQ:CTMX

$2.75 -0.24 (-8.03%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.84 +0.09 (+3.31%)

As of 06/13/2025 07:57 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Monopar Therapeutics NASDAQ:MNPR

$33.52 -0.30 (-0.89%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$33.74 +0.22 (+0.66%)

As of 06/13/2025 06:12 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Tyme Technologies NASDAQ:TYME

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time